Profil
Zina Affas Besse currently holds the position of Director at Eyenuk, Inc. since 2022.
Also holds the role of Director at Alydia Health, Inc. The role of Director at LimmaTech Biologics AG has been held since 2023.
Serves as Partner at AXA IM Alts since 2022.
Acts as Advisor at LHGP Asset Management LLP (Private Equity).
Education includes undergraduate and doctorate degrees from the University of Nottingham Malaysia.
Aktive Positionen von Zina Affas Besse
| Unternehmen | Position | Beginn |
|---|---|---|
Alydia Health, Inc.
Alydia Health, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes medical devices | Direktor/Vorstandsmitglied | - |
Eyenuk, Inc.
Eyenuk, Inc. Medical SpecialtiesHealth Technology Develops and manufactures diabetic retinopathy diagnostic devices | Direktor/Vorstandsmitglied | 17.10.2022 |
LHGP Asset Management LLP (Private Equity)
LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management seeks investment opportunities located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for late stage capital requirements with an average investment size of USD 10 million. | Berater | - |
LimmaTech Biologics AG
LimmaTech Biologics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops vaccines for prevention of life-threatening diseases | Direktor/Vorstandsmitglied | 09.10.2023 |
Ausbildung von Zina Affas Besse
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
LHGP Asset Management LLP (Private Equity)
LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management seeks investment opportunities located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for late stage capital requirements with an average investment size of USD 10 million. | Finance |
Eyenuk, Inc.
Eyenuk, Inc. Medical SpecialtiesHealth Technology Develops and manufactures diabetic retinopathy diagnostic devices | Health Technology |
Alydia Health, Inc.
Alydia Health, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes medical devices | Health Technology |
LimmaTech Biologics AG
LimmaTech Biologics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops vaccines for prevention of life-threatening diseases | Health Technology |
University of Nottingham Malaysia
University of Nottingham Malaysia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















